Quest Diagnostics Inc vs J B Hunt Transport Services Inc — how do they compare? Quest Diagnostics Inc trades at $230.78 (market cap $25.48B), while J B Hunt Transport Services Inc trades at $228.28 (market cap $21.45B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and J B Hunt Transport Services Inc for 45 Days on average.
| DGX | JBHT | |
|---|---|---|
Market Cap | $25.48B | $21.45B |
Volume | 941,866 | 1,028,680 |
Sector | Health | Industrials |
52-Week High | $247.45 | $298.41 |
52-Week Low | $173.49 | $137.09 |
Typical Hold Time | 56 Days | 45 Days |
Enterprise Value | $31.23B | $22.59B |
Dividend Yield | 1.49% | 0.79% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
JBHT trades at $228.91, up 2.82% today, with a bearish technical signal and neutral oscillators. The company reported revenue of $12.00B in 2025, with net income of $598.28M and a net margin of 5.31%. Recent earnings have consistently beaten estimates, but the stock faces headwinds from rising costs and multiple securities class action investigations announced in late September 2026.
The outlook is mixed: strong analyst consensus with a $289.40 price target suggests upside, but near-term risks from cost pressures and legal scrutiny cloud the picture. Earnings growth and freight demand remain key drivers, yet investor sentiment is cautious amid profit warnings and volatile diesel prices.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →